

## RESEARCH / INVESTIGACIÓN

# Assessing HeberFast® Line Gavac, a lateral flow immunochromatographic system for the rapid detection of anti-Bm86 antibodies in Gavac vaccinated cattle

Milagros Vargas-Hernández<sup>1</sup>, Yeni Hernández Lorenzo<sup>2</sup>, Viviana Pluma Perez<sup>2</sup>, Isabel Rosales-García<sup>2</sup>, Sunamit Rodríguez-Mendez<sup>2</sup>, Enrique Pérez-Cruz<sup>3</sup>, Daymi Abreu-Remedios<sup>3</sup>, Carlos Montero-Espinosa<sup>1</sup>, Ayme Oliva-Cardenas<sup>1</sup>, Elaine Santana-Rodríguez<sup>1</sup>, Danny Pérez-Pérez<sup>1</sup>, Yusmel Sordo-Puga<sup>1</sup>, Yohandy Fuentes-Rodríguez<sup>1</sup>, Alianne Fundora-Llera<sup>1</sup>, Carlos A. Duarte<sup>1</sup>, Ernesto Galbán-Rodríguez<sup>4</sup>, Carlos Hernandez-Diaz<sup>3</sup>, Dayami Dorta Hernandez<sup>3</sup>, Ivis Pasaron Rodríguez<sup>3</sup>, Marisela Suarez-Pedroso<sup>1</sup>

DOI. 10.21931/RB/2021.06.03.4

**Abstract:** *Rhipicephalus Boophilus microplus* cattle tick is a scourge for livestock production. The infestations produced by this pathogen are incompletely contained by chemical treatments, with the associated environmental pollution risks. Vaccination against cattle ticks has emerged as a feasible and environmentally friendly strategy to control tick-borne diseases. In this setting, Gavac® vaccine has proven effective in decreasing cattle tick populations through antibody responses against the tick Bm86 antigen, as part of an Integrated Control Program. However, animal vaccination programs require easy and ready-to-use screening tests to follow up the immune response in vaccinated animals under field conditions. This study reports the evaluation HeberFast® Line Gavac, a lateral flow immunochromatographic system for the rapid detection of anti Bm86 antibodies in vaccinated cattle. The system was tested on 598 serum samples taken from immunized animals, arranged in three groups according to their anti-Bm86 antibody response in ELISA (209 high, 150 medium or 239 low and 100 samples from non-immunized animals). The HeberFast® Line Gavac system was assessed for sensitivity, specificity, and concordance against the ELISA reference test. Consistency was evaluated among production batches and inter-analyst reading-independent consistency at two moments: ten minutes after completing the test and after strip drying. The system showed high sensitivity (81.6%, 82.2%, and 81%), specificity (96.7, 94.6, and 93.3%), and agreement with the ELISA reference test (75%; 74%, and 71%) for high, medium and low anti-Bm86 sera, respectively. The effectiveness of the diagnosis was 87.6; 87.1; 85.9 for high, medium, and low antibody titers, respectively. Consistency among production batches and analysts was documented, and no significant differences between evaluation times were found. These results indicate that HeberFast® Line Gavac is a valuable tool for the serological surveillance of Gavac vaccinated cattle.

**Key words:** Cattle tick, vaccination, antibody screening strip, lateral flow immunoassay, Bm86, Gavac®.

## Introduction

*Rhipicephalus (Boophilus) microplus* cattle tick is a scourge for livestock production in tropical and subtropical areas. Ticks cause significant losses due to their direct weakening effects in cattle and through tick-borne diseases, ultimately causing animal death<sup>1</sup>. In Cuba, an Integrated Management Program for cattle tick control has been implemented nationwide. This program comprises the combination of Gavac®, a recombinant vaccine against cattle tick, with chemical acaricide treatments, scheduled according to the infestation index, and other measures for the biological, mechanical, immunological, and genetic control of the plague. The application of the vaccine has effectively sparse the number of acaricide treatments required, thereby reducing the environmental pollution risks and diminishing a 98% the deaths rates caused by hemoparasites<sup>2-4</sup>.

The active ingredient of Gavac® is the tick gut Bm86 protein. Anti-Bm86 antibodies induced upon vaccination will attach to the gut epithelium of suckling ticks, with deleterious effects on their populations and the size of their progeny<sup>5,6</sup>. Regular immunizations are required to maintain protective anti-Bm86 antibody titers in the blood of the animals<sup>5-8</sup>.

Commonly, antibody titers in sera of immunized animals are monitored through antigen-specific Enzyme-Linked Immunosorbent Assays (ELISA) tests, high efficiency, and specificity. However, such assays are troublesome under field conditions, time-consuming, and require specialized laboratory facilities and qualified personnel to perform and evaluate the results

objectively. Thus, a fast and easy-to-use screening test is needed to implement and evaluate ongoing, and future cattle tick vaccination campaigns under field conditions.

Therefore, this study aimed to evaluate the performance of HeberFast® Line Gavac, a fast chromatographic screening test for the detection of anti-Bm86 antibodies, and its concordance with the reference ELISA test used in the laboratory. The main parameters to compare were sensitivity, specificity, and consistency.

## Materials and methods

### Material and Reagents

### Ethical statement

Blood was extracted from cattle following an experimental protocol elaborated according to the ethics guidelines for animal care<sup>9</sup> and approved by the Ethics Committee of the Center for Genetic Engineering and Biotechnology (CIGB).

### Serum collection and measurement of anti-Bm86 antibody titers by ELISA

Positive and negative anti-Bm86 antibody blood was collected from animals in units either under tick control programs

<sup>1</sup> Departamento de Biotecnología Animal, Dirección de Investigaciones Agropecuarias, Centro de Ingeniería Genética y Biotecnología, La Habana, Cuba.

<sup>2</sup> Unidad de Laboratorios Centrales de Sanidad Agropecuaria (ULCSA), Ministry of Agriculture, Cuba.

<sup>3</sup> Centro de Ingeniería Genética y Biotecnología, Santi Spiritus, Cuba.

<sup>4</sup> Editorial Elfos Scientiae, Dirección de Promoción y Distribución Nacional, CIGB, Cuba.

with Gavac® vaccination or without vaccination. Blood was taken from healthy cattle, regardless of age, sex, or reproductive categories, and the sera were stored at -20°C until use.

ELISA measured the level of anti-Bm86 antibodies in sera. Briefly, ELISA microplates (Polysorp, Nunc, USA) were coated with Bm86 protein at 2 µg/mL and incubated overnight at 4°C. Plates were washed with PBS-Tween 20 (0.05%), and blocked with 1% skimmed milk for 1 h at 37°C. Sera was next diluted 1:500 in PBS-Tween 20 (0.05%) and 100 µL added to each well, and further incubated for 1 h at 37°C. Next, a rabbit anti-bovine IgG antibody conjugated to horseradish peroxidase was added for 30 min at 37°C. Finally, the reaction was developed with 0.5 mg/mL ortho-phenylenediamine and 0.015 % H<sub>2</sub>O<sub>2</sub>, and the reaction stopped 10 min later with H<sub>2</sub>SO<sub>4</sub> (1%). The optical density (OD) was measured at 492 nm in an ELISA plate reader (Sunrise, Austria). A standard curve made with five 1:2 serial dilutions of an anti Bm86 positive reference serum reference, starting with 1:640, was used to interpolate the OD values of each serum. The anti Bm86 antibody values were expressed as absorbance units (AU)/mL. Three groups were formed according to the results of this evaluation:

Group 1. High responders: 209 positive samples with anti-Bm86 antibody values higher than 1000 AU/mL.

Group 2. Medium responders (gray zone): 150 samples with anti-Bm86 antibody values between 530 and 1000 AU/mL (minimum protective titers).

Group 3. Low responders: 239 samples with non-protective (negative) antibody values lower than 530 AU/mL.

Another group of negative sera with 100 samples from non-immunized animals was conformed.

HeberFast® Line Gavac

### Bm86 protein and its conjugation to colloidal gold

The active pharmaceutical ingredient in GAVAC® vaccine was supplied by its manufacturer, the Center for Genetic Engineering and Biotechnology of Camagüey, Cuba. The conjugation of the Bm86 protein to colloidal gold was carried out according to Bailes *et al.*, 2012<sup>10</sup> using homemade 20 nm colloidal gold particles. The protein was solubilized in 0.005 mol/L of sodium chloride. The colloidal gold was also adjusted to pH 7 with 0.1 M K<sub>2</sub>CO<sub>3</sub>.

The following flocculation test first determined the amount of protein in relation to a fixed volume of gold: 500 µL of 20 nm colloidal gold at pH 7 were mixed with 100 µL of the protein solution in a range between 4 and 20 µg. The mixture was homogenized and incubated for 10 min at room temperature, and 500 µL of 10% sodium chloride solution was added to each reaction mixture. Finally, the conjugate content in the mixture was quantified by measuring the absorbance at 530 nm in a spectrophotometer (Thermo Scientific GENESYS 10S UV-Vis, Madison, USA).

Once the optimal amount of protein had been selected, the reaction was conducted for 30 min at -20 °C -25 °C, stirring at 300 rpm. The free sites on the colloidal gold particles were blocked with an adequate volume of 10% BSA, for a final concentration of 0.5 %. The final mixture was centrifuged at 16000 x g for 1 hour at 4°C. The conjugate obtained (pellet) was suspended in 0.1 M TBS, BSA 1% pH 7.0, and diluted up to an absorbance of 40 at a wavelength of 530 nm.

### Preparation of the immunoreactive strip

The strip components were nitrocellulose (NC) membrane of 15 µm (MDI, type CNPC-SS12-L2-H50, dimensions 7,5 x

26 cm, 1,5 cm of NC), pad for the antigen-gold conjugate (MDI, type PTR-5, dimensions 2,7 x 26 cm), and absorbent pad (MDI, type AP080, dimensions 3,5 x 26 cm). The conjugate was diluted to an absorbance of 20, at a wavelength of 530 nm and dispensed onto the antigen-gold conjugate pad.

The Bm86 protein, dissolved at 4 mg/mL in phosphate buffer saline (PBS) was absorbed into the membrane in the test line. The mixture of the control line components consisted of a monoclonal antibody against Bm86 protein provided by the Center for Genetic Engineering and Biotechnology of Sancti Spiritus, Cuba at 4 mg/mL, and 0.2 mg/mL of poly L-lysine, dissolved in PBS.

Both the macroporous material and the nitrocellulose membrane were sprayed with the BioDotQuanti 2000, BioJet, England, and then dried in an oven at 37 °C, for 30 min. The NC membrane cards were blocked for 1h at room temperature in blocking solution (0.02% (v/v) Tween 20, 0.02% (w/v) sodium azide, 5% (w/v) sucrose, and 0.5% bovine seroalbumin (BSA), dissolved in PBS. Later they were dried in the oven at 37 °C for 1 h.

### Test strip assembly

The NC membrane was coupled in the center of polyvinyl chloride support. The absorbent pad and the conjugate pad were glued by overlapping 1 mm at the top and bottom of the NC Membrane, respectively. The sample pad was then glued by overlapping 2 mm on the bottom of the conjugate pad. The master assembled card was cut into 4 mm wide strips using a CM5000-guillotine-cutter (BioDot, Irvine, USA).

### Immunochromatographic assay

The rapid, one-step, and visual reading lateral flow immunoassay (LFIA), branded HeberFast® Line Gavac, consists of a strip of nitrocellulose (NC) membranes to detect antibodies against the Bm86 antigen in bovine serum. The membrane consists of two phases: a fixed phase composed of the Bm86 protein as a capture biomolecule for the specific immunoglobulins present in the serum and a mobile phase containing a protein-colloidal gold marker conjugate, which finally develops the reaction with a specific dye.

Each strip was introduced into 80 µL of bovine serum (previously diluted 1:8 in buffer). The diluted sera migrated by capillarity within the macroporous material, dissolving the Bm86 conjugate labeled with colloidal gold. Two independent reactions could be observed in the virtual window. If the sample was positive, the immune complex reacted with the Bm86 protein attached to the NC membrane, forming a first horizontal redline Positive Line (PL). For all samples, the free conjugate was captured in a second red horizontal line Control Line (CL) where a polyclonal anti-IgG murine antibody is fixed to the solid phase.

### Performance evaluation

Strips were used to detect antibody responses in 698 samples of bovine sera, from 598 vaccinated and 100 unvaccinated animals. The results of the samples were interpreted at two moments, at the end of the reaction 10 min after the sample was applied and once the strip dried. LFIA tested samples in triplicate. The specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), efficacy as well as kappa coefficient (K), were determined.

### Kappa coefficient (K)

The Kappa coefficient was calculated to assess the level of significance of the agreement between the ELISA and the LFIA. The following ranges and their respective performance criteria were defined: 0.81-1.00, almost perfect agreement; 0.61-0.80, reasonable agreement, 0.60-0.41, moderate agreement; 0.40-0.21, discrete agreement, 0.20-0.01 insignificant agreement, and lower than 0.01, no agreement<sup>11</sup>.

### Batch to batch consistency

The samples from all panels were all evaluated by the three batches of strips (Gavac1501, Gavac1502, and Gavac1503). Results were considered valid for samples with coincident results with two different strip batches.

### Inter-analyst interpretation

Three analysts read each sample, and results were regarded as valid when two out of the three observers coincided.

### Statistical analysis

The LFIA and the ELISA reference system results were statistically compared using the epidemiological analysis of tabulated data (EPIDAT) software, version 3.1<sup>12</sup>. Concordance, sensitivity, specificity, efficacy, positive and negative predictive values, batch to batch consistency, and inter-analyst interpretation were compared. Statistical significance was considered for a 95 % confidence interval.

## Results

Evaluation of the panel of samples from unimmunized animals.

All sera from unimmunized animals were negative. Only one signal appeared in the diagnostic control line, which guarantees the validity of the test. This represented a 100% of specificity for the system. Four representative samples from this group are shown in figure 1.

### Evaluation of samples from immunized animals

All the strips used were accepted as valid, as the control line indicating their quality and reliability was observed. The intensity of the test capture region line varied depending on the concentration of immunoglobulins in the sample.

The overall false positive rate fluctuated between 3.34% and 6.69%, while a range of 4.78%-5.26% was found for false-negative results for the different lots and times evaluated. As expected, the percentage of false negative and false positive values was highly dependent on anti-Bm86 antibodies in the samples. Samples from group 2 (medium responders) showed the greatest incongruities when compared to the reference ELISA (36% - 38.7% of false negatives) (Table 1). The percentage of false-negative values dropped to 4.8%-5.2% in the group of high responders. On the other hand, the percentage of false positives in the ELISA negative sera was only 3.4-7.1%. Figure 1 shows 4 representative samples from each of the three groups evaluated.

The general agreement of the immunochromatographic strips with respect to ELISA was good for the 3 batches evaluated based on the kappa coefficient (Gav1501, Gav1502, and Gav1503) (Table 2).


The results of sensitivity, specificity, efficacy (test validity index), positive and negative predictive values, and confidence intervals of the 3 batches in studies are shown in Table 3.

### Consistency between batches

The agreement among the three batches of strips evaluated (Gav1501, Gav1502, and Gav1503) is shown in Table 4. All batches exhibited high kappa coefficients, which indicate a good, or almost perfect degree of concordance. These results demonstrated the consistency of the manufacturing process.

### Independence of the analysts

The concordance among the three analysts that read the assays ranged from good to almost perfect as the concentration of immunoglobulins increased. The results are shown in Table 5. The samples evaluated in the two moments gave no significant differences.



**Figure 1.** Evaluation of sera from Gavac immunized animals and unvaccinated controls. Four representative samples per group were included. A: unvaccinated control group; B: high responders, (>1000 AU/mL); C: medium responders (530 - 1000 AU/mL); D: low responders (>530 AU/mL).

anti Bm86 ELISA values (n)	Lot Gav1501				Lot Gav1502				Lot Gav1503			
	reading 1		reading 2		reading 1		reading 2		reading 1		reading 2	
<b>Group 1</b> <b>&gt; 1000 AU/mL</b> <b>(209)</b>	P	N	P	N	P	N	P	N	P	N	P	N
	198	11	198	11	199	10	199	10	199	10	199	10
	94.8 %	5.2%	94.8 %	5.2%	95.2 %	4.8%	95.2 %	4.8%	95.2 %	4.8%	95.2 %	4.8%
<b>Group 2</b> <b>530-1000 AU/mL</b> <b>(150)</b>	P	N	P	N	P	N	P	N	P	N	P	N
	95	55	96	54	96	54	97	53	92	58	92	58
	63.3%	36.7%	64%	36%	64%	36%	64.7%	35.3%	61.3 %	38.7%	61.3 %	38.7%
<b>Group 3</b> <b>&lt;530 AU/mL</b> <b>(239)</b>	P	N	P	N	P	N	P	N	P	N	P	N
	8	231	8	231	13	226	13	226	16	223	17	222
	3.4%	96.6%	3.4%	96.6%	5.4%	94.6%	5.4%	94.6%	6.7%	93.3%	7.1%	92.9%

Reading 1: reading done immediately after the end of the assay (10 min); reading 2: reading done after the strip was dried. The percentages represent the % of agreement of the positive or negative values with respect to the ELISA.

**Table 1.** Evaluation of the diagnostic strips with a panel of positive anti-Bm86 sera.

Parameters	Reading	Gav1501	Gav1502	Gav1503
<b>Kappa</b>	1	0.75	0.74	0.71
	2	0.74	0.74	0.71
<b>CI</b>	1	0.70-0.80	0.69-0.79	0.66-0.77
	2	0.69-0.80	0.69-0.80	0.66-0.77
<b>Agreement</b>	1	Good	Good	Good
	2	Good	Good	Good

CI, confidence intervals

**Table 2.** General agreement between the immunochromatographic assay and the reference ELISA.

Parameters	Reading	Gav1501	Gav1502	Gav1503
<b>Sensitivity</b>	1	81.6 (77.5-85.8)	82.2 (78-86.3)	81 (76.9-85.2)
	2	81.9 (77.8-86.3)	82.4 (78.4-86.5)	81 (76.9-85.2)
<b>Specificity</b>	1	96.7 (94.2-99.2)	94.6 (91.5-97.6)	93.3 (89.9-96.7)
	2	95.4 (92.5-98.3)	94.1 (91-97.3)	92.9(89.4-96.4)
<b>Efficacy</b>	1	87.6 (84.9-90.3)	87.1 (84.4-89.9)	85.9 (83- 88.8)
	2	87.3 (84.5-90)	87.1 (84.4-89.9)	85.8 (82.9- 88.7)
<b>PPV</b>	1	97.3 (95.4-99.3)	95.8 (93.4-98.2)	94.8 (92.2-97.4)
	2	96.4 (94.2-98.6)	95.5 (93-98)	94.5 (91.8-97.2)
<b>NPV</b>	1	77.8 (72.9-82.7)	77.9 (73-82.9)	76.6 (71.6-81.7)
	2	77.8 (72.9-82.7)	78.1 (73.2-83)	76.5 (71.5-81.6)

Average (95 % confidence interval). PPV: positive predictive value, NPV: negative predictive value.

**Table 3.** Performance of the immunochromatographic system.

## Discussion

Tick mitigation strategies are part of a long tradition and focus on the local application of acaricides or the search for biological products that reduce the impact of the problem<sup>13</sup>. The use of the Gavac® immunogen within a control program decreases the reproductive parameters of the tick through the specific antibodies developed in the immunized animals<sup>14</sup>. Moreover, the fast development of anti-Bm86 antibody levels guarantees herds immunity and the effective control of tick populations<sup>4</sup>.

In this setting, the development of rapid, specific, sensitive, and economically feasible diagnostic methods such as

LFIA is of paramount relevance in veterinary medicine. They support the massive screening of samples in a shorter time under field conditions and the early detection of pathogens, further providing specific treatments and monitoring for the control epidemiological units<sup>15</sup>.

In this study, the performance of the HeberFast® Line Gavac immune screening test was evaluated for detecting anti-Bm86 antibody titers in sera of immunized cattle. The sensitivity and specificity of the immunochromatographic system for the three batches under study were in the 81-82% and 92-95% ranges, respectively. Similar results have been previously reported for the use of LFIA strips for massive screening. For instance, the direct Sensitive Membrane Antigen Rapid Test

Batches	Positivity criteria	Reading	Parameters				
			Kappa	IC 95 %	P. estad. z	Consistency	
Gav150 1	Positive	1	0.9252	0.8177-1.0000	23.1678	Almost	
		2	0.9321	0.8350-1.0000	23.3405	Perfect	
	Gray zone	1	0.8782	0.8135-0.9429	18.6291	Almost	
		2	0.8866	0.8236-0.9495	18.8067	Perfect	
	Negative	1	0.7459	0.5548-0.9368	19.9723	Good	
		2	0.7221	0.5500-0.8941	19.3360		
	Gav150 2	Positive	1	0.8915	0.7640-1.0000	22.3240	Almost
			2	0.8915	0.7640-1.0000	22.3240	Perfect
Gray zone		1	0.9226	0.8697-1.0000	19.5719	Almost	
		2	0.9319	0.8818-0.9820	19.7690	Perfect	
Negative		1	0.9494	0.8768-1.0000	25.4224	Almost	
		2	0.9526	0.8847-1.0000	25.5071	Perfect	
Gav150 3		Positive	1	0.9661	0.8959-1.0000	24.1902	Almost
			2	0.9661	0.8959-1.0000	24.1902	Perfect
	Gray zone	1	0.9344	0.8862-0.9826	19.8218	Almost	
		2	0.9443	0.9001-0.9886	20.0325	Perfect	
	Negative	1	0.8925	0.7972-0.9877	23.8984	Almost	
		2	0.8981	0.8079-0.9883	24.0491	Perfect	

**1: reading immediately after the end of the assay (10 min); 2: reading after the strip was dried**

**Table 4.** Consistency in production.

(SMART®; New Horizons Diagnostics Corp., USA) and the direct Pathogen Detection Kit® (PDK; Intelligent Monitoring Systems, USA) were reported to display 100 % sensitivity for cholera diagnosis in diarrheal and semi-formed stool samples, and in intestinal contents of corpses. Furthermore, 100 % specificity was also attained with SMART®, while the same parameter for direct PDK® ranged between 77.4% and 85.7%, depending on sample type<sup>16</sup>. In immunochromatographic studies to detect *Giardia* spp. and *Cryptosporidium* spp. in feces, 58-97.2 % sensitivity and 99-100 % specificity were reported<sup>17,18</sup>.

In summary, diagnostic tests must perform with high specificity and sensitivity to avoid false positives or false negative results. This is more relevant when diagnosing severe illnesses or other conditions able to compromise herd health and integrity and devoid of any contingency measures other than animal sacrifice. A misdiagnosis can lead to serious economic losses in those situations, as for treatable pests such as Foot and Mouth Disease, African Swine Fever, Classical Swine Fever, and similar<sup>19,20</sup>.

Since the HeberFast® Line Gavac strip will be applied to determine the immune status of animals vaccinated with Gavac®, the specificity of this test is more critical than its sensitivity. Consequently, the assay must exhibit a low fraction of false positives when assessing post-vaccination immunity. The

assay's specificity was in the range 92.9-95.4% for the three batches tested, well above its sensitivity values (81-82.4%).

In veterinary medicine, lateral flow immunoassays have been developed for various purposes; detection of diseases in companion and farm animals to achieve better results in the care and development of animals, for example, Parvovirus<sup>21</sup>, Newcastle<sup>22</sup>, Avian infectious bronchitis virus<sup>23</sup>, African swine fever<sup>24</sup> and Babesiosis<sup>25</sup>. The rapid detection of these diseases reduces the economic losses. Immunochromatographic methods have also been developed to detect antibiotics and analogs in milk<sup>26</sup>, which is greatly important for food safety.

In general, this test offers advantages and benefits, especially in the field, due to its fast and safe use and relatively low production costs. Moreover, it does not require equipment for readouts, and the results are easily interpreted with the naked eye, with high specificity and sensitivity in just 10 min. Finally, this immunoscreening test has been developed to work with serum, a sample that can be easily collected and processed.

HeberFast® Line Gavac is the first rapid kit worldwide for the detection of antibodies against the Bm86 protein. Its introduction in the field could facilitate the follow-up of the immune response against any vaccine based on this antigen and determine the level of immunity achieved in the vaccinated herds.

Analyst	Positivity criteria	Reading	Parameters			
			Kappa	IC 95 %	P. estad. z	Consistency
Analyst 1	Positive	1	0.8643	0.7185-1.0000	21.6410	Almost Perfect
		2	0.8643	0.7185-1.0000	21.6410	
	Gray Zone	1	0.7113	0.6189-0.8037	15.0891	Good
		2	0.7008	0.6068-0.7947	14.8658	
	Negative	1	0.6283	0.4695-0.7871	16.8247	Good
		2	0.6283	0.4695-0.7871	16.8247	
Analyst 2	Positive	1	0.8184	0.6665-0.9703	20.4936	Almost Perfect
		2	0.8184	0.6665-0.9703	20.4936	
	Gray Zone	1	0.7164	0.6238-0.8089	15.1969	Good
		2	0.7157	0.6227-0.8088	15.1828	
	Negative	1	0.6665	0.4843-0.8487	17.8478	Good
		2	0.6558	0.4799-0.8316	17.5602	
Analyst 3	Positive	1	0.8950	0.7657-1.0000	22.4101	Almost Perfect
		2	0.8950	0.7657-1.0000	22.4101	
	Gray Zone	1	0.7150	0.6223-0.8078	15.1684	Good
		2	0.7041	0.6096-0.7985	14.9362	
	Negative	1	0.7221	0.5414-0.9028	19.3360	Good
		2	0.6746	0.5014-0.8478	18.0639	

1: Reading once the technique

Table 5. Analyst Interpretation.

## Conclusions

The HeberFast® Line Gavac immunochromatographic system allows the determination of the anti-Bm86 serological status quickly and straightforwardly to a large number of samples in field conditions with minimal effort. The introduction of this test would significantly improve the follow-up of the antibody response to GAVAC in all the country as part of the Integrated Control Program for cattle tick control.

## Acknowledgements

This work was carried out thanks to the collaboration with the Unit of Central Laboratories of Agricultural Health (ULC-SA), Ministry of Agriculture, Cuba.

## Bibliographic references

- Rodriguez-Vivas RI, Jonsson NN, Bhushan C. Strategies for the control of Rhipicephalus microplus ticks in a world of conventional acaricide and macrocyclic lactone resistance. *Parasitology research* 2018; 117:3-29.
- Valle MR, Mendez L, Valdez M, et al. Integrated control of Boophilus microplus ticks in Cuba based on vaccination with the anti-tick vaccine Gavac. *Experimental & applied acarology* 2004; 34:375-82.
- Suarez PM, Méndez, M.L., Valdez, M., Souza, R.M., Camargo, A.J.R., Constanza, N.V., Ascanio, E.E. Control de las infestaciones de la garrapata Boophilus microplus en la ganadería Cubana y en regiones de Latinoamérica con la aplicación del inmunógeno Gavac® dentro de un programa de lucha integral. Documento sexta conferencia Electrónica - Redectopar 2007.
- Suarez M, Rubi J, Pérez D, et al. High impact and effectiveness of Gavac™ vaccine in the national program for control of bovine ticks Rhipicephalus microplus in Venezuela. *Livestock Science* 2016; 187:48-52.
- Willadsen P, Kemp D. Vaccination with 'concealed' antigens for tick control. *Parasitology Today* 1988; 4:196-8.
- de la Fuente J, Rodríguez M, Redondo M, et al. Field studies and cost-effectiveness analysis of vaccination with Gavac against the cattle tick Boophilus microplus. *Vaccine* 1998;16:366-73.
- Lamberti J, Signorini A, Mattos C, et al. Evaluation of the recombinant vaccine against Boophilus microplus in grazing cattle in Argentina. *Recombinant Vaccines for the Control of the Cattle Tick* (ed De la Fuente, J) 1995:205-27.
- Vargas M, Montero C, Sanchez D, et al. Two initial vaccinations with the Bm86-based Gavacplus vaccine against Rhipicephalus (Boophilus) microplus induce similar reproductive suppression to three initial vaccinations under production conditions. *BMC veterinary research* 2010;6:43.

9. Ethical Guidelines for the Use of Animals in Research. 2018. (Accessed 23/10/2021, 2020).
10. Bailes J, Mayoss S, Teale P, Soloviev M. Gold nanoparticle antibody conjugates for use in competitive lateral flow assays. *Nanoparticles in Biology and Medicine*: Springer; 2012:45-55.
11. Landis J, Koch G. The measurement of observer agreement for categorical data. *Biometrics* 1977:159-74.
12. EPIDAT 3.1. Una herramienta para el análisis epidemiológico de datos tabulados. Infomed, 2005. (Accessed 14//05/2020, 2020, at <http://www.sld.cu/sitios/revsalud/temas.php?idv=1178>.)
13. Las garrapatas del bovino y los agentes de enfermedad que transmiten en escenarios epidemiológicos de cambio climático. Guía para el manejo de garrapatas y adaptación al cambio climático. Instituto Interamericano de Cooperación para la Agricultura (IICA), 2016. (Accessed 12/06/2020, 2020, at <http://creativecommons.org/licenses/by-sa/0/igo/>.)
14. Vargas-Hernández M, Santana-Rodríguez E, Sordo-Puga Y, et al. Stability, safety and protective immunity of Gavac® vaccine subjected to heat stress. *Biotecnología Aplicada* 2018; 35:1221-7.
15. Sastre P, Gallardo C, Monedero A, et al. Development of a novel lateral flow assay for detection of African swine fever in blood. *BMC veterinary research* 2016; 12:1-8.
16. Bolaños HM, Acuña MT, Serrano AM, et al. Desempeño de los sistemas Cholera-SMART® y Pathogen-Detection-Kit® en el diagnóstico rápido del cólera. *Revista Panamericana de Salud Pública* 2004; 16:233-41.
17. Corripio IF, Cisneros MJG, Ormaechea TG. Diagnóstico de las parasitosis intestinales mediante detección de coproantígenos. *Enfermedades Infecciosas y Microbiología Clínica* 2010; 28:33-9.
18. Gutiérrez-Cisneros MJ, Martínez-Ruiz R, Subirats M, Merino FJ, Millán R, Fuentes I. Evaluación de dos métodos inmunocromatográficos comerciales para el diagnóstico rápido de *Giardia duodenalis* y *Cryptosporidium* spp. en muestras de heces. *Enfermedades Infecciosas y Microbiología Clínica* 2011; 29:201-3.
19. Knowles N, Samuel A. Molecular epidemiology of foot-and-mouth disease virus. *Virus research* 2003; 91:65-80.
20. OIE. Chapter 15.2. Infection with classical Swine fever virus. *Terrestrial Animal Health code*. In: OIE, ed. 2019.
21. Sharma C, Singh M, Upmanyu V, et al. development and evaluation of a gold nanoparticle-based immunochromatographic strip test for the detection of canine parvovirus. *Archives of virology* 2018; 163:2359-68.
22. Li Q, Wang L, Sun Y, et al. Evaluation of an immunochromatographic strip for detection of avian avulavirus 1 (Newcastle disease virus). *Journal of Veterinary Diagnostic Investigation* 2019; 31:475-80.
23. Liu I-L, Lin Y-C, Lin Y-C, Jian C-Z, Cheng I-C, Chen H-W. A novel immunochromatographic strip for antigen detection of avian infectious bronchitis virus. *International journal of molecular sciences* 2019; 20:2216.
24. Wang X, Ji P, Fan H, et al. CRISPR/Cas12a technology combined with immunochromatographic strips for portable detection of African swine fever virus. *Communications biology* 2020; 3:1-8.
25. Stuart Tayebwa D, Magdy Beshbishy A, Batiha GE-S, et al. Assessing the immunochromatographic test strip for serological detection of bovine babesiosis in Uganda. *Microorganisms* 2020; 8:1110.
26. Peng J, Liu L, Kuang H, Cui G, Xu C. Development of an icELISA and immunochromatographic strip to detect norfloxacin and its analogs in milk. *Food and Agricultural Immunology* 2017; 28:288-98.

**Received:** 2 February 2021

**Accepted:** 2 June 2021